You have say and think there were always going to many challenges and obstacles launching a new drug into a patient cohort with very serious and sensitive health issues. I believe Acadia and Neuren management have done an excellent job rolling Daybue out. The roll out will only improve as they come to better understand all the different reactions and improvements these beautiful children are having using Daybue. This report today was music to my ears, it looks like we’ll do 400 mill us this year and probably double that the year after (I’d like to know what forecast after this year)… with 2591 knocking down the door… as they say do the math
You have say and think there were always going to many...
-
- There are more pages in this discussion • 578 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.12 |
Change
0.770(5.37%) |
Mkt cap ! $1.927B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.12 | $14.35 | $3.990M | 268.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1038 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.13 | 469 | 10 |
View Market Depth
| Last trade - 14.05pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |